User: Guest  Login
Title:

Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer Results of a phase II study in elderly patients or patients with impaired performance status.

Document type:
Journal Article; Review
Author(s):
Abbrederis, K; Lorenzen, S; von Weikersthal, LF; Vehling-Kaiser, U; Schuster, T; Rothling, N; Peschel, C; Lordick, F
Abstract:
BACKGROUND: Three-weekly docetaxel is active in patients with advanced esophagogastric cancer but myelosuppression may make this schedule unsuitable for some patient groups such as elderly, pretreated, or poor performance status patients. PATIENTS AND METHODS: Eligible patients were chemonaive with Karnofsky index /=70 years) included, 87% had Karnofsky index /=100 days (disease stabilization rate: 36%). Overall response rate was 9%; median overall survival was 7.0 months. CONCLUSIONS: Weekly d...     »
Journal title abbreviation:
Crit Rev Oncol Hematol
Year:
2008
Journal volume:
66
Journal issue:
1
Pages contribution:
84-90
Language:
eng
Fulltext / DOI:
doi:10.1016/j.critrevonc.2007.12.001
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/18243012
Print-ISSN:
1040-8428
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Medizinische Statistik und Epidemiologie
 BibTeX